Contract advances Mirasol® System for the
treatment of whole blood
Terumo BCT is working with the U.S. Army Medical Research and Materiel
Command to develop a U.S. Food and Drug Administration (FDA)-approved
whole blood pathogen reduction device.
Under the terms of the contract, the DoD will fund $3.46M over the
next three years (FY2013-FY2016) to complete the required tasks
necessary to submit for FDA approval of the Mirasol system for whole
The DoD has the option to equally share in the cost of additional
safety and efficacy studies of pathogen-reduced whole blood and
clinical trials as appropriate for a pre-market approval (PMA)
application to FDA:
Under these options, the DoD would fund a maximum of $11.3M over
the next four years.
Terumo BCT would cost share a maximum of $15.1M over the same
Cost sharing is the portion of a project cost not borne by the
The new cost-share contract effort expands the Mirasol system
development efforts initiated with the DoD in 2007.
The Mirasol system treats blood with a combination of riboflavin
(vitamin B2), a non-toxic naturally occurring compound, and
ultraviolet light torender a broad range of
disease-causing viruses, such as West Nile virus and HIV, bacteria and
parasites less pathogenic.
LAKEWOOD, Colo.--(BUSINESS WIRE)--
Terumo BCT has been awarded a U.S. Department of Defense (DoD)
cost-share contract worth up to $29.9M to advance the technology.aspx&esheet=50732440&newsitemid=20131021005265&lan=en-US&anchor=Mirasol+System&index=1&md5=a2e85fe3d91209a834c6e3a223ee1fb3" rel="nofollow">Mirasol
System for the treatment of donated whole blood used in emergency
transfusions in deployed military forces.
Raymond Goodrich, PhD, Terumo BCT, Vice
President of Scientific and Clinical Affairs
“We are pleased to partner with the U.S. Army in advancing the
development of the Mirasol system for whole blood, a critical resource
developed to help improve the medical support capabilities for our
soldiers in the field. With this collaboration, we aim to provide the
best possible transfusion medicine option for war fighters and further
Terumo BCT's mission to improve lives through innovation, quality and